Efficacy and safety of current therapies for difficult-to-treat rheumatoid arthritis: a systematic review and network meta-analysis.

Qin-Yi SuJing LuoYan ZhangQian LiZhong-Qing JiangZi-Rong WenYu-Ying WangMo-Ran ShiSheng-Xiao Zhang

Published in: Journal of translational medicine (2024)

Tocilizumab and rituximab have better efficacy and safety in the treatment of D2T RA, and the 8 mg/4w dose of tocilizumab may be the first choice for achieving disease remission.

Keyphrases

rheumatoid arthritis
disease activity
rheumatoid arthritis patients
ankylosing spondylitis
juvenile idiopathic arthritis
interstitial lung disease
diffuse large b cell lymphoma
systemic lupus erythematosus
decision making
hodgkin lymphoma
systemic sclerosis